Fractyl Health Unveils Groundbreaking Pre-Clinical Proof of Concept Results for its Rejuva® Pancreatic Gene Therapy Platform for Metabolic Diseases at the American Society of Gene & Cell Therapy Congress

Rejuva device & procedure reliably and successfully targets pancreas with Adeno Associated Virus (AAV), potentially enabling gene therapy to address pancreatic diseases for the first time

Rejuva platform and genetic medicines offer potential for reversal of Type 2 Diabetes with a single point-in-time local administration of durable GLP-1-based genetic medicines

Excerpt from the Press Release:

LEXINGTON, Mass.–(BUSINESS WIRE)– Fractyl Health today presented key findings from its preclinical Rejuva® program at the American Society of Gene & Cell Therapy (ASGCT) Congress. The oral presentation, “A Pancreatic Gene Therapy Delivery Platform for the Treatment of Type 2 Diabetes,” highlighted proof-of-concept work of the Rejuva platform and its potential to revolutionize the treatment of type 2 diabetes (T2D) and obesity.

Importantly, the data presented today establishes the feasibility and proof-of-concept efficacy of AAV viral delivery to the pancreas and dose-dependent efficacy of GLP-1 based genetic medicines to restore the pancreas’ ability to produce insulin and thereby dramatically improve blood sugar control and change the trajectory of diabetes – without any unexpected safety signals observed thus far.

“What is exciting to me about the Rejuva platform is that we now have substantial proof of concept in animal models that local delivery of AAV to the pancreas may not only be feasible, but could have profound effects on metabolic control,” said Christopher C. Thompson, MD, Director of Endoscopy at Brigham and Women’s Hospital and Professor at Harvard Medical School. “By targeting the pancreas, we may be able to reverse the pathology in that organ that drives T2D.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release